The use of SGLT2 inhibitors for cardio-renal protection is known to correct anemia in diabetes, heart failure, chronic kidney disease, and chronic obstructive pulmonary disease [35,36,37,38]. Here, SLC5A2 is linked to diabetes mellitus.